Send to

Choose Destination
J Biol Regul Homeost Agents. 2018 May-Jun;32(3):693-697.

Apatinib treatment in extensive metastatic advanced thymic carcinoma.

Author information

Department of Radiation Oncology, Harbin Medical University Cancer Hospital, Harbin, China.
Department of Gynecology, Harbin Medical University Cancer Hospital, Harbin, China.
Department of Pathology, Harbin Medical University Cancer Hospital, Harbin, China.


Apatinib is a novel oral, anti-tumor, angiogenic-targeting drug that can selectively target vascular endothelial growth factor receptor-2 (VEGFR-2). In clinical trials, this new tyrosine kinase inhibitor (TKI) has been shown to be an effective and safe treatment for a variety of malignancies. Currently, there is a lack of studies of patients with thymic carcinoma; therefore, we present a case of advanced thymic carcinoma treated with apatinib after chemotherapy failure with multiple lung metastases. This patient has been taking a dose of 500 mg of apatinib per day, and his efficacy has achieved partial response (PR), according to the RECIST 1.1 standard, and progression-free survival (PFS) is 6.3 months at this point. Apatinib will continue as his maintenance treatment. During the treatment, drug-related toxicity and side effects were tolerable. Thus, apatinib may be a meaningful option for the treatment of advanced metastatic thymic carcinoma after chemotherapy failure.

[Indexed for MEDLINE]

Supplemental Content

Loading ...
Support Center